Condition
Chronic Myelogenous Leukemia, Accelerated Phase
Total Trials
2
Recruiting
1
Active
2
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 2 trials
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed with results
Key Signals
Data Visualizations
Phase Distribution
2Total
Not Applicable (1)
P 1 (1)
Trial Status
Recruiting1
Active Not Recruiting1
Clinical Trials (2)
Showing 2 of 2 trials
NCT03842696Phase 1Active Not Recruiting
Vorinostat for Graft vs Host Disease Prevention in Children, Adolescents and Young Adults Undergoing Allogeneic Blood and Marrow Transplantation
NCT05794880Not ApplicableRecruiting
MCW Alpha/Beta T-Cell and B-Cell Depletion With Targeted ATG Dosing
Showing all 2 trials